Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes
Tóm tắt
Over the past decades there have been exciting and rapid developments of highly specific molecules to bind cancer antigens that are overexpressed on the surfaces of malignant cells. Nanomedicine aims to exploit these ligands to generate nanoscale platforms for targeted cancer therapy, and to do so with negligible off-target effects. Aptamers are structured nucleic acids that bind to defined molecular targets ranging from small molecules and proteins to whole cells or viruses. They are selected through an iterative process of amplification and enrichment called SELEX (systematic evolution of ligands by exponential enrichment), in which a combinatorial oligonucleotide library is exposed to the target of interest for several repetitive rounds. Nucleic acid ligands able to bind and internalize into malignant cells have been extensively used as tools for targeted delivery of therapeutic payloads both in vitro and in vivo. However, current cell targeting aptamer platforms suffer from limitations that have slowed their translation to the clinic. This is especially true for applications in which the cargo must reach the cytosol to exert its biological activity, as only a small percentage of the endocytosed cargo is typically able to translocate into the cytosol. Innovative technologies and selection strategies are required to enhance cytoplasmic delivery. In this review, we describe current selection methods used to generate aptamers that target cancer cells, and we highlight some of the factors that affect productive endosomal escape of cargoes. We also give an overview of the most promising strategies utilized to improve and monitor endosomal escape of therapeutic cargoes. The methods we highlight exploit tools and technologies that can potentially be incorporated in the SELEX process. Innovative selection protocols may identify aptamers with extended biological functionalities that allow effective cytosolic translocation of therapeutics. This in turn may facilitate successful translation of these platforms into clinical applications.
Từ khóa
Tài liệu tham khảo
Sun, 2014, Engineered nanoparticles for drug delivery in cancer therapy, Angew. Chem. Int. Ed. Engl., 53, 12320, 10.1002/anie.201403036
Srinivasarao, 2015, Principles in the design of ligand-targeted cancer therapeutics and imaging agents, Nat. Rev. Drug Discov., 14, 1, 10.1038/nrd4519
Guidotti, 2017, Cell-Penetrating Peptides: From Basic Research to Clinics, Trends Pharmacol. Sci., 38, 406, 10.1016/j.tips.2017.01.003
Marqus, 2017, Evaluation of the use of therapeutic peptides for cancer treatment, J. Biomed. Sci., 24, 21, 10.1186/s12929-017-0328-x
Khvorova, 2017, The chemical evolution of oligonucleotide therapies of clinical utility, Nat. Biotechnol., 35, 238, 10.1038/nbt.3765
Juliano, 2016, The delivery of therapeutic oligonucleotides, Nucleic Acids Res., 44, 6518, 10.1093/nar/gkw236
Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387
Liu, 2015, Cancer targeted therapeutics: From molecules to drug delivery vehicles, J. Control. Release, 219, 632, 10.1016/j.jconrel.2015.08.041
Danhier, 2010, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release, 148, 135, 10.1016/j.jconrel.2010.08.027
Allen, 2002, Ligand-targeted therapeutics in anticancer therapy, Nat. Rev. Cancer, 2, 750, 10.1038/nrc903
Steichen, 2012, A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics, Eur. J. Pharm. Sci., 48, 416, 10.1016/j.ejps.2012.12.006
Zhou, 2014, Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy, Mol. Ther. Nucleic Acids, 3, e169, 10.1038/mtna.2014.21
Sanna, V., Pala, N., and Sechi, M. (2014). Targeted therapy using nanotechnology: Focus on cancer. Int. J. Nanomed., 467–483.
Gomes de Castro, M.A., Höbartner, C., and Opazo, F. (2017). Aptamers provide superior stainings of cellular receptors studied under super-resolution microscopy. PLoS ONE, 12.
Zhou, 2016, Aptamers as targeted therapeutics: Current potential and challenges, Nat. Rev. Drug Discov., 16, 181, 10.1038/nrd.2016.199
Prakash, 2015, Aptamers and Their Significant Role in Cancer Therapy and Diagnosis, Biomedicines, 3, 248, 10.3390/biomedicines3030248
Bruno, 2013, A review of therapeutic aptamer conjugates with emphasis on new approaches, Pharmaceuticals (Basel), 6, 340, 10.3390/ph6030340
Urmann, 2017, Aptamer-modified nanomaterials: Principles and applications, BioNanoMaterials, 18, 1
Dowdy, 2017, Overcoming cellular barriers for RNA therapeutics, Nat. Biotechnol., 35, 222, 10.1038/nbt.3802
Wittrup, 2015, Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown, Nat. Biotechnol., 33, 1, 10.1038/nbt.3298
Dassie, 2009, Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors, Nat. Biotechnol., 27, 839, 10.1038/nbt.1560
Prakash, 2014, Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice, Nucleic Acids Res., 42, 8796, 10.1093/nar/gku531
Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0
Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121
McKeague, 2012, Challenges and opportunities for small molecule aptamer development, J. Nucleic Acids, 2012, 748913, 10.1155/2012/748913
Dausse, 2009, Aptamers: A new class of oligonucleotides in the drug discovery pipeline?, Curr. Opin. Pharmacol., 9, 602, 10.1016/j.coph.2009.07.006
Ng, 2006, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov., 5, 123, 10.1038/nrd1955
Vinores, 2006, Pegaptanib in the treatment of wet, age-related macular degeneration, Int. J. Nanomed., 1, 263
Lao, 2015, Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation, ACS Nano, 9, 2235, 10.1021/nn507494p
Maier, 2016, From selection hits to clinical leads: Progress in aptamer discovery, Mol. Ther. Methods Clin. Dev., 5, 16014, 10.1038/mtm.2016.14
Mallikaratchy, 2017, Evolution of complex target SELEX to identify aptamers against mammalian cell-surface antigens, Molecules, 22, 1, 10.3390/molecules22020215
Mercier, M.-C., Dontenwill, M., and Choulier, L. (2017). Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers. Cancers (Basel), 9.
Li, N., Nguyen, H.H., Byrom, M., and Ellington, A.D. (2011). Inhibition of Cell Proliferation by an Anti-EGFR Aptamer. PLoS ONE, 6.
Shangguan, 2006, Aptamers evolved from live cells as effective molecular probes for cancer study, Proc. Natl. Acad. Sci. USA, 103, 11838, 10.1073/pnas.0602615103
Somasunderam, 2010, Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44, Biochemistry, 49, 9106, 10.1021/bi1009503
Volk, D.E., and Lokesh, G.L.R. (2017). Development of Phosphorothioate DNA and DNA Thioaptamers. Biomedicines, 5.
Wilner, 2012, An RNA alternative to human transferrin: A new tool for targeting human cells, Mol. Ther. Nucleic Acids, 1, e21, 10.1038/mtna.2012.14
Maier, 2016, A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry, Mol. Ther. Nucleic Acids, 5, e321, 10.1038/mtna.2016.32
Lupold, 2002, Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen 1, Cancer Res., 62, 4029
Bates, 2009, Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer, Exp. Mol. Pathol., 86, 151, 10.1016/j.yexmp.2009.01.004
Soundararajan, 2008, The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells, Cancer Res., 68, 2358, 10.1158/0008-5472.CAN-07-5723
Soundararajan, 2009, Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells, Mol. Pharmacol., 76, 984, 10.1124/mol.109.055947
Raddatz, 2008, Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting, Angew. Chemie., 47, 5190, 10.1002/anie.200800216
Opazo, 2015, Modular Assembly of Cell-targeting Devices Based on an Uncommon G-quadruplex Aptamer, Mol. Ther Nucleic Acids, 4, e251, 10.1038/mtna.2015.25
Thiel, 2012, Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers, Nucleic Acids Res., 40, 6319, 10.1093/nar/gks294
Chen, 2008, Aptamer-based endocytosis of a lysosomal enzyme, Proc. Natl. Acad. Sci. USA, 105, 15908, 10.1073/pnas.0808360105
Porciani, 2014, Two Interconvertible Folds Modulate the Activity of a DNA Aptamer Against Transferrin Receptor, Mol. Ther. Acids, 3, e144, 10.1038/mtna.2013.71
Iaboni, 2016, Targeting Insulin Receptor with a Novel Internalizing Aptamer, Mol. Ther. Acids, 5, e365, 10.1038/mtna.2016.73
Ozer, 2014, New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization, Mol. Ther. Nucleic Acids, 3, e183, 10.1038/mtna.2014.34
Baneyx, 2004, Recombinant protein folding and misfolding in Escherichia coli, Nat. Biotechnol., 22, 1399, 10.1038/nbt1029
Mortensen, 2005, Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli, Microb. Cell. Fact., 4, 1, 10.1186/1475-2859-4-1
Liu, 2009, Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis, Biol. Chem., 390, 137, 10.1515/BC.2009.022
Vinkenborg, 2012, Aptamer-based affinity labeling of proteins, Angew. Chem. Int. Ed. Engl., 51, 9176, 10.1002/anie.201204174
Kruspe, S., and Giangrande, P. (2017). Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. Biomedicines, 5.
Byrom, 2012, A general RNA motif for cellular transfection, Mol. Ther., 20, 616, 10.1038/mt.2011.277
Burke, 2012, Cell-penetrating RNAs: New keys to the castle, Mol. Ther., 20, 251, 10.1038/mt.2011.306
Porciani, 2015, Aptamer-Mediated Codelivery of Doxorubicin and NF-κB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells, Mol. Ther. Nucleic Acids, 4, e235, 10.1038/mtna.2015.9
Rohde, 2015, A Universal Aptamer Chimera for the Delivery of Functional microRNA-126, Nucleic Acid Ther., 25, 141, 10.1089/nat.2014.0501
Mcknight, 1980, Transferrin Gene Expression. Effects of nutritional iron deficiency, J. Biol. Chem., 255, 144, 10.1016/S0021-9258(19)86276-2
Austin, 2004, Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin, Mol. Biol. Cell., 15, 5268, 10.1091/mbc.e04-07-0591
Zumrut, 2016, Ligand-guided selection of aptamers against T-cell Receptor-cluster of differentiation 3 (TCR-CD3) expressed on Jurkat.E6 cells, Anal. Biochem., 512, 1, 10.1016/j.ab.2016.08.007
Muthukrishnan, 2012, Improving the endosomal escape of cell-penetrating peptides and their cargos: Strategies and challenges, Pharmaceuticals, 5, 1177, 10.3390/ph5111177
Li, 2015, Discovery and Characterization of a Peptide That Enhances Endosomal Escape of Delivered Proteins in Vitro and in Vivo, J. Am. Chem. Soc., 137, 14084, 10.1021/jacs.5b05694
Kacsinta, 2016, Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics, Sci. Rep., 6, 32301, 10.1038/srep32301
Salomone, 2012, A novel chimeric cell-penetrating peptide with membrane-disruptive properties for efficient endosomal escape, J. Control. Release, 163, 293, 10.1016/j.jconrel.2012.09.019
Sahay, 2013, Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling, Nat. Biotechnol., 31, 653, 10.1038/nbt.2614
Wagenaar, 2015, Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells, Nucleic Acids Res., 43, 1204, 10.1093/nar/gku1367
Wang, 2016, The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA, Mol. Ther., 24, 1, 10.1038/mt.2016.179
Cruz, 2000, Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol, J. Biol. Chem., 275, 4013, 10.1074/jbc.275.6.4013
Liu, 2013, A universal protein tag for delivery of siRNA-aptamer chimeras, Sci. Rep., 3, 3129, 10.1038/srep03129
Bates, 1999, Antiproliferative activity of G-rich oligonucleotides correlates with protein binding, J. Biol. Chem., 274, 26369, 10.1074/jbc.274.37.26369
Rosenberg, 2014, A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma, Invest. New Drugs, 32, 178, 10.1007/s10637-013-0045-6
Teng, 2010, A new paradigm for aptamer therapeutic AS1411 action: Uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism, Cancer Res., 70, 8617, 10.1158/0008-5472.CAN-10-0920
Shams, 2015, Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation, Mol. Oncol., 9, 1392, 10.1016/j.molonc.2015.03.012
Boyacioglu, 2013, Dimeric DNA Aptamer Complexes for High-capacity–targeted Drug Delivery Using pH-sensitive Covalent Linkages, Mol. Ther. Nucleic Acids, 2, e107, 10.1038/mtna.2013.37
Hernandez, 2013, Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers, Pharmaceuticals (Basel), 6, 295, 10.3390/ph6030295
Qian, 2015, Monitoring the cytosolic entry of cell-penetrating peptides using a pH-sensitive fluorophore, Chem. Commun., 51, 2162, 10.1039/C4CC09441G